Genetic Immunity announces first patient dosed in trial with DermaVir patch for HIV

Genetic Immunity, a US/Hungarian clinical-stage company focused on development of nanomedicines for targeted immune amplification, today announced it has treated the first subject in a Phase II clinical study to evaluate DermaVir Patch.

DermaVir Patch, the Company's lead nanomedicine candidate for treatment-na? HIV-infected individuals, is designed to amplify de novo HIV-specific memory T-cell responses of HIV-infected individuals and improve the ability of their own immune system to control the disease.

To read the Entire at News-Medical.net article click here.